Summary The 28-item GHQ was used to assess psychiatric morbidity in 302 women attending for routine breast cancer screening, 300 women attending for further investigation of a positive screening result and 150 women referred for investigation of breast symptoms. The GHQ-28 was administered on arrival at the relevant clinic and three months later. Medical records were used to determine the outcome of the clinic attendance. Women were classified into routinely screened women, women with false positive screening results, symptomatic women with a benign diagnosis, newly diagnosed cancer patients and previously treated cancer patients. When tested on arrival at the clinic, 25% of routinely screened, 30% of women with false positive results and 35% of symptomatic women with benign conditions were probable cases of psychiatric morbidity. The only statistically significant difference was between the routinely screened and symptomatic benign groups. Levels of anxiety were significantly higher in those with false positive results and in the symptomatic benign group than in the routinely screened. Three months later the prevalence of probable psychiatric morbidity had fallen to 19% in both the routinely screened and those with false positive results but remained significantly higher in the symptomatic benign group (31%). Probable cases of psychiatric morbidity among newly detected cancer patients rose from 34 to 46% over the 3-month period. Among women who had had breast cancer diagnosed in the past prevalence remained at 21 %. The prevalence of probable psychiatric morbidity in screened women is similar to that in the general population. Among women referred for further investigation because of a false positive screening result prevalence was only slightly increased and there was no evidence of a sustained increase in anxiety. Provided that delays are kept to a minimum and that women are kept informed, a breast cancer screening programme does not increase psychiatric morbidity. Further research is required in cancer patients to determine whether those diagnosed in asymptomatic women have a higher and more sustained degree of psychiatric morbidity than those diagnosed in women who are aware of symptoms.
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Concern has been expressed that screening for breast cancer may have adverse psychological effects. The invitation for screening may make women more aware of their vulnerability and hence increase anxiety. Recalling women who are found to have an abnormality on screening for further investigation (currently 5-10% of those screened in the UK) may cause distress which is hard to alleviate even when further investigations are negative. Those who are symptom-free on screening but are found to have cancer could find it especially hard to adapt to the diagnosis (Maguire, 1982) .
The first concern has been partially investigated in Edinburgh (Dean et al., 1986) . It was found that women attending for screening had no excess psychiatric morbidity compared to other women in the same age-group, (although little is yet known about morbidity in those who did not attend in response to invitation). Our study set out to investigate immediate and persistent psychiatric morbidity in those referred for further investigation because of an abnormal screening result, and to compare these women with attenders for screening and with women being investigated for breast cancer because of symptoms.
Methods
As part of the UK Trial of Early Detection of Breast Cancer (1981) , over the past 8 years women aged 45-71 registered with general practitioners in South-West Surrey Health District have been invited for annual breast cancer screening. The attendance rate at the time of this study was 65% overall and 73% among those being invited for the first time either because they had just reached 45 years or because they had recently moved into the district. An earlier study (Calnan, 1985) patient clinic for investigation of breast symptoms were included. Eighty-two per cent of the women recruited at the screening clinic and 80% of those recruited at review clinics had been screened in previous years.
On arrival at the relevant clinic, before seeing the doctor or undergoing mammography, each woman was asked by a research nurse to complete the 28-item version of the General Health Questionnaire (Goldberg, 1978) . A condition placed on the psychological study was that it should not reduce compliance or interfere with the efficiency of the main trial screening programme. The GHQ-28 is brief and acceptable and, using score >4, provides a valid measure of comparison between groups when the object is to detect anxiety or depression of fairly recent onset. Three months later, the same women were again asked to complete the GHQ-28 and then to answer questions about their clinic experiences (these will be discussed more fully in a separate paper). The 3-month repeat questionnaire was administered at home by a research nurse to all women with a score of five or more on the initial GHQ-28, and to 60% of those with lower scores. The remaining 40% who scored low on the initial GHQ-28 were sent the repeat questionnaire by post.
Clinical records were used to determine the outcome of each woman's attendance. The women have been categorised as follows: (A) attenders at screening in whom no abnormality was found; (B) review clinic attenders whose further investigation showed no cancer (false positives); (C) symptomatic women whose investigation showed no cancer; (D) symptomatic or review clinic women in whom breast cancer was diagnosed in this episode; (E) Changes in score were the same for those low initial scorers who were sent postal questionnaires as for those visited (Mann-Whitney U test, P = 0.7, n.s.). The 3-month GHQ-28 scores for the routinely screened and false positive groups did not differ significantly between women attending screening for the first time and those who had been screened in the past.
When analysed by the component scales of the GHQ-28, scores on the anxiety scale had fallen significantly in the false positive group (P<0.0001). Within the new cancer patient group there were significant increases in the somatic symptoms scale (P<0.001) and the social dysfunction scale (P <0.0001). Table IV and Table II further illustrate the similarity between the false positive and routinely screened groups on the second occasion with 3% more of the false positives having anxiety symptoms but 8% fewer having somatic symptoms and 7% more having total scores of zero. Thirteen (5%) out of 253 questioned about the screening examination complained of embarrassment during examination and mammography.
Discussion
The prevalence of scores of five or more, indicating probable psychiatric morbidity, among women attending for routine screening is in the middle of the range reported in other community-based studies of women in this age range (Williams et al., 1986) . This adds weight to the conclusion of the Edinburgh study (Dean et al., 1986) that attendance for screening does not increase psychiatric morbidity.
The prevalence of probable psychiatric morbidity among women in the false positive group was slightly, but not significantly, higher than in those attending for routine screening. But anxiety symptoms were -not surprisingly -more common, and a few women admitted to experiencing panic while waiting for their review clinic appointment. However, the GHQ-28 at 3 months showed no lasting increase in anxiety or in psychiatric morbidity as a whole. This is reassuring in that one of the worries expressed about the current screening programme is that the anxiety induced in these women with false positive results outweighs the benefit of prolongation of life for some cancer patients (Wright, 1986 ).
An underlying reason for this concern may be the experience that many clinicians have in managing women with symptomatic benign abnormalities. These women showed a prevalence of probable psychiatric morbidity higher than either the routinely screened or the false positive groups, but similar to that found in studies of women attending GP surgeries (Finlay-Jones & Burvill, 1978) . Moreover, their raised prevalence of high GHQ-28 scores persisted for 3 months, even after a diagnosis of breast cancer had been ruled out. These women may well belong to a group who present underlying psychological distress somatically.
Those with newly diagnosed cancer are a small but important group. Asymptomatic women attending for screening probably believe they are free of cancer and the unexpected news that they have cancer may be harder to assimilate than in women warned of the possibility of cancer by their symptoms. Moreover, they may also worry because they have no confidence that any recurrence will manifest itself by symptoms. But the number of breast cancers in this study is too small to make a valid comparison between the screen-detected cases and the symptomatic cases. A larger study is needed to assess whether the method of breast cancer detection affects the degree and duration of psychiatric morbidity.
This study indicates that breast cancer screening need not lead to any sustained increase in the prevalence of psychiatric morbidity in a community. The study was, however, conducted in a well-established screening programme and one in which clinical examination was included. First attenders showed slightly more anxiety than others at the time of screening but were insufficient in number for firm conclusions to be drawn. The effect on psychological morbidity of introducing the national mammographic screening programme should be monitored to ensure that it too is minimal. The comments of screened women indicate the importance of minimising delays in the diagnostic process and of maintaining full and frank communication throughout.
